Focused On-demand Library for Fanconi anemia core complex-associated protein 20

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q6NZ36

UPID:

FAP20_HUMAN

Alternative names:

FANCA-associated protein of 20 kDa; Fanconi anemia-associated protein of 20 kDa

Alternative UPACC:

Q6NZ36; A6PW39; A6PW40; A6PW41; A8MQT6; F2Z2L4; Q6ZT64; Q71M24; Q96ND7

Background:

The Fanconi anemia core complex-associated protein 20, also known as FANCA-associated protein of 20 kDa, plays a pivotal role in DNA repair mechanisms. It is essential for the recruitment of the Fanconi anemia (FA) complex to DNA interstrand cross-links (ICLs), facilitating their repair. This protein recognizes and binds 'Lys-63'-linked ubiquitin at ICLs, a critical step in the DNA damage response, and interacts with REV1 to promote translesion synthesis.

Therapeutic significance:

Understanding the role of Fanconi anemia core complex-associated protein 20 could open doors to potential therapeutic strategies. Its involvement in DNA repair mechanisms highlights its potential as a target for developing treatments for genetic disorders related to DNA damage and repair processes.